Cargando…
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
Over the past few years, a number of anticancer drugs have been developed that specifically target kinases known to be oncogenic. The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment of chronic myeloid leukaemia, alth...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395307/ https://www.ncbi.nlm.nih.gov/pubmed/14710199 http://dx.doi.org/10.1038/sj.bjc.6601507 |